TD Cowen reiterates Buy on Prime Medicine stock after arbitration win
TD Cowen reiterated a Buy on Prime Medicine (NASDAQ:PRME) after an arbitration win against Beam Therapeutics. A tribunal ruled PM647 is within Prime’s field under a 2019 collaboration agreement and Prime owes no monetary damages. Prime plans an IND/CTA filing for PM647 in Q3 2026, with initial data in 2027. H.C. Wainwright set an $8 target; Citizens set $6.


